Proteomics and Metabolomics Shared Resource Project Summary/Abstract The Proteomics and Metabolomics Shared Resource (PMSR) consists of a Fred Hutchinson Cancer Research Center (FHCRC)-based Proteomics/Metabolomics laboratory and a University of Washington-South Lake Union (UW-SLU) laboratory. The Proteomics section of the PMSR was formed in November 2002 with the goal of providing cost-effective high performance liquid chromatography and mass spectrometry-based proteomics services to Cancer Consortium (Consortium) members. The Proteomics resource's mission is to provide high quality service in a timely manner for small- and large-scale qualitative and quantitative proteomics analyses, protein modification characterization, and targeted proteomic analyses. These services have evolved from small-scale identification of protein complexes in model systems and identifying modifications on highly purified proteins to large-scale biomarker discovery/validation experiments in serum samples and phosphoproteomics analysis of animal organs. The PMSR received an outstanding merit assessment in 2008. In 2010, the PMSR was expanded to include metabolomics research and related resources through the joint recruitment of Daniel Raftery, Ph.D., a recognized leader in metabolomics research, to FHCRC and the University of Washington (UW). Along with the proteomics services mentioned above, the resource now provides untargeted profiling of aqueous metabolites and lipids (lipidomics), targeted profiling of metabolites from numerous metabolic pathways via mass spectrometry and nuclear magnetic resonance spectroscopy, and isotope tracer capabilities. The PMSR is also rapidly developing mass spectrometry phospholipid analysis. The resource is committed to developing and implementing new proteomics and metabolomics tools in order to uncover the molecular details that influence cancer biology and to support development of diagnostic and clinical tests. Scientific operations of the Proteomics and Metabolomics resource are divided between FHCRC and UW- medicine sites. Dr. Gafken oversees all operations at FHCRC and Dr. Raftery oversees those at UW. Drs. Gafken and Raftery meet on a monthly to coordinate activities, or more frequently if needed for specific projects. All proteomics-based projects are performed at FHCRC while metabolomics-based projects are divided between the two sites. Metabolomics projects for which established, routine assays are available are performed at FHCRC while those metabolomics projects that are non-routine and require significant development are performed at UW. As new metabolomics assays are developed and refined at the UW site, FHCRC-based staff will be trained on these protocols to make them more widely available as a service. All NMR capabilities and NMR-related projects will be conducted at UW-SLU.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA015704-44S1
Application #
9842435
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
He, Min
Project Start
Project End
Budget Start
2019-01-01
Budget End
2019-12-31
Support Year
44
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Cheng, Heather H (2018) The resounding effect of DNA repair deficiency in prostate cancer. Urol Oncol 36:385-388
Poudel, Kumud R; Roh-Johnson, Minna; Su, Allen et al. (2018) Competition between TIAM1 and Membranes Balances Endophilin A3 Activity in Cancer Metastasis. Dev Cell 45:738-752.e6
Holly, Mayumi K; Smith, Jason G (2018) Adenovirus infection of human enteroids reveals interferon sensitivity and preferential infection of goblet cells. J Virol :
Eaton, Keith D; Romine, Perrin E; Goodman, Gary E et al. (2018) Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility. J Thorac Oncol 13:649-659
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Gauthier, Jordan; Turtle, Cameron J (2018) Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med 66:50-52
Graves, Scott S; Parker, Maura H; Stone, Diane et al. (2018) Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:50-54
Amundsen, Susan K; Smith, Gerald R (2018) The RecB helicase-nuclease tether mediates Chi hotspot control of RecBCD enzyme. Nucleic Acids Res :
Méndez, Eduardo; Rodriguez, Cristina P; Kao, Michael C et al. (2018) A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 24:2740-2748
Buckley, Sarah A; Percival, Mary-Elizabeth; Othus, Megan et al. (2018) A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study. Leuk Lymphoma :1-7

Showing the most recent 10 out of 1267 publications